A Phase II Randomized, Open-Label, Two-Arm Study of Green Tea and a Water Control in Men Scheduled for Prostatectomy
- To determine the effects of drinking 6 cups of green tea vs water for an average of 6
weeks prior to prostatectomy on prostate tumor grade and stage (i.e., biopsy and
prostatectomy specimen), margin status of prostatectomy specimen, biomarkers of
prostate cancer development and progression (i.e., serum prostate-specific antigen
[PSA], proliferation [Ki-67], apoptosis [TUNEL, Bax/Bcl-2 ratio], inflammation [NFkB],
and oxidative status [8OhdG/dG ratio]) in patients with adenocarcinoma of the prostate.
- To compare changes in prostate tissue biomarkers (prostate biopsy tissue vs
corresponding radical prostatectomy tissue).
- To determine the concentrations of total and free tea polyphenols (i.e., EGCG, EC, EGC,
ECG) and theaflavins, as well as 4'-O-methyl-epigallocatechin gallate (4'-O-MeEGC),
EGCG-4'-O-glucuronide, EGCG-4"-O-glucuronide, 3M4HPAA, 4HPAA, and 3,4DHPAA in human
serum, urine, and prostate tissue after green tea, black tea, and water consumption.
- To determine the subject's genotype of catechol-O-methyltransferase (COMT),
UDPglucuronosyltransferases (UGT1A1) and sulfotransferase (SULT1A1), and the effect of
the intervention on gene expression of COMT, UGTs, and SULTs in prostate tissue.
- To determine the antiproliferative effect on human serum before and after tea
supplementation in an ex vivo LNCaP cell culture assay and to investigate the mechanism
of the antiproliferative activity.
- To determine the effect of tea supplementation on serum IGF-1, IGFBP-3, testosterone,
SHBG, and DHEA-sulfate.
OUTLINE: This is a multicenter, randomized study. Patients are randomized to 1 of 2
- Arm I: Patients receive 6 cups of green tea daily for 2-8 weeks in the absence of
- Arm II: Patients receive 6 cups of water daily for 2-8 weeks in the absence of
Patients undergo radical prostatectomy.
Blood and urine samples, as well as tissue from diagnostic biopsy and radical prostatectomy
specimens, are obtained for laboratory correlative studies. Samples are assessed by IHC,
high-performance liquid chromatography, or mass spectrometry for changes in prostate tumor
grade, stage, and margin status; concentrations of total and free tea polyphenols (i.e.,
EGCG, EC, EGC, ECG), theaflavins, and conjugated/colonic tea metabolites; biomarkers of
prostate cancer development and progression (i.e., serum PSA, proliferation [i.e., Ki-67],
apoptosis [i.e., TUNEL, Bax/Bcl-2 ratio], inflammation [i.e., NFkB]), and oxidative status
(i.e., 8OhdG/dG ratio); and genotype and gene expression of metabolizing enzymes (i.e.,
COMT, UGT, and SULT). Serum samples are also assessed by ex vivo LNCaP cell culture assay
for antiproliferative activity and by competitive chemiluminescent immunoassay for
concentrations of PSA, IGF-1, IGFBP-3, testosterone, SHBG, and DHEA-sulfate.
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Biomarkers of prostate cancer development and progression
Susanne M. Henning, PhD, RD
Jonsson Comprehensive Cancer Center
United States: Food and Drug Administration
|Veterans Affairs Medical Center - West Los Angeles||Los Angeles, California 90073|
|Jonsson Comprehensive Cancer Center at UCLA||Los Angeles, California 90095-1781|